Levetiracetam Tablet, Film Coated
Product Images NDC 70010-524

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70010-524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1000-30s-count-label (1000 mg 30s Count Label)

1000-30s-count-label (1000 mg 30s Count Label)
Levetiracetam Tablets, USP 1000 mg film-coated tablets label displaying a package size of 30 tablets. The label includes storage instructions, a medication guide notice, a barcode, and manufacturing information for Granules India Limited and Granules Pharmaceuticals Inc. This prescription drug label also notes it is Rx only.*
FDA Label Image

250-30s-count-label (250 mg 30s Count Label)

250-30s-count-label (250 mg 30s Count Label)
Levetiracetam Tablets, USP 250 mg film-coated tablets carton label showing 30 tablets per container. The label includes storage information, dosage guide reference, and manufacturer details: manufactured by Granules India Limited, India, and manufactured for Granules Pharmaceuticals Inc., Chantilly, VA. The label features NDC 70010-521-03 and a medication guide URL for patient information.*
FDA Label Image

500-30s-count-label (500 mg 30s Count Label)

500-30s-count-label (500 mg 30s Count Label)
Levetiracetam Tablets USP 500 mg film-coated tablets packaging label shows a 30-tablet bottle. It includes storage instructions, a medication guide notice, and manufacturer information for Granules India Limited and Granules Pharmaceuticals Inc. The label features barcode and lot/expiry placeholders.*
FDA Label Image

750-30s-count-label (750 mg 30s Count Label)

750-30s-count-label (750 mg 30s Count Label)
Levetiracetam Tablets, USP 750 mg film-coated tablets label. The packaging contains 30 tablets, labeled for prescription use only. The label includes dosage strength (750 mg), pharmacist instructions, storage conditions, medication guide information, manufacturer Granules India Limited, and labeler Granules Pharmaceuticals Inc. Barcodes and revision date 06/2022 are visible.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
Bar chart showing responder rates with ≥50% reduction from baseline in Study 1 for Levetiracetam tablets. The chart compares placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). Statistical significance versus placebo is noted for the Levetiracetam groups.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar graph showing responder rates (≥50% reduction from baseline) in Study 2 Period A for Levetiracetam tablets at 1000 mg/day and 2000 mg/day doses compared to placebo. The graph displays percentages of patients responding, with Levetiracetam 2000 mg/day having the highest responder rate, followed by 1000 mg/day, and the lowest for placebo. Statistical significance versus placebo is indicated.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing placebo and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, ranging from 0% to 45%. The placebo group (N=104) shows a 14.4% responder rate, while the Levetiracetam group (N=180) shows a 39.4% responder rate with a statistical significance marker versus placebo.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A bar graph comparing responder rates (≥ 50% reduction from baseline) between placebo and Levetiracetam groups in Study 4. The Levetiracetam group shows a higher responder rate at 44.6% versus 19.6% for placebo, with a statistically significant difference indicated.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A bar chart titled "Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5" comparing the percentage of patients responding to Placebo and Levetiracetam. The chart shows approximately 19.6% response rate for Placebo (N=51) and 43.1% for Levetiracetam (N=58), with a notation indicating statistical significance versus placebo.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing placebo and Levetiracetam. The y-axis shows percentage of patients from 0% to 100%. Placebo group (N=84) shows 45.2% responders, while Levetiracetam group (N=79) shows 72.2% responders, marked statistically significant versus placebo.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of levetiracetam, the active ingredient. The diagram shows the molecular arrangement including a pyrrolidone ring, an ethyl group, and an amide group characteristic of levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.